Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)

BACKGROUND: Although targeted agents have been gradually applied in the treatment of HER2-mutated non-small cell lung cancer (NSCLC) in recent years, patients’ therapeutic demands are far from being met. PATHER2 was the first phase 2 trial to explore the efficacy and safety of the HER2-targeted tyro...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Guangjian, Xu, Haiyan, Yang, Yaning, Zhang, Shuyang, Xu, Fei, Hao, Xuezhi, Li, Junling, Xing, Puyuan, Hu, Xingsheng, Liu, Yutao, Wang, Lin, Lin, Lin, Wang, Zhijie, Duan, Jianchun, Wang, Jie, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422117/
https://www.ncbi.nlm.nih.gov/pubmed/36031613
http://dx.doi.org/10.1186/s12916-022-02470-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422117/
https://www.ncbi.nlm.nih.gov/pubmed/36031613
http://dx.doi.org/10.1186/s12916-022-02470-6

Ejemplares similares